Autologous stem cell transplantation for non-Hodgkin's lymphoma: Comparison of radiation-based and chemotherapy-only preparative regimens

F. Gutierrez-Delgado, D. G. Maloney, O. W. Press, J. Golden, L. A. Holmberg, Richard Maziarz, H. Hooper, C. D. Buckner, F. R. Appelbaum, W. I. Bensinger

Research output: Contribution to journalArticle

31 Citations (Scopus)

Abstract

The aim of this study was to compare toxicity and efficacy of total body irradiation (TBI), cyclophosphamide (CY) and etoposide (E) (TBI/CY/E) vs busulfan, melphalan and thiotepa (Bu/Mel/T) in patients receiving autologous stem cell infusion (ASCI) for malignant lymphoma (NHL). Between September 1990 and July 1998, 351 patients with NHL were treated with TBI/CY/E (n = 221) or Bu/Mel/T (n = 130) followed by ASCI. Patients in first, or second remission, first responding or untreated relapse were defined as having less advanced disease before transplantation. The median follow-up was 5 years (range 1-9) and 3.5 years (1-6) for patients receiving TBI/CY/E and Bu/Mel/T, respectively. The cumulative probabilities of survival, event-free survival (EFS) and relapse at 5 years were 44%, 32%, 49% following TBI/CY/E and 42%, 34% and 42% following Bu/Mel/T. The probability of EFS at 5 years for patients who had prior dose-limiting radiation (n = 59) was 32% after Bu/Mel/T therapy. Transplant-related mortality was 16% for TBI/CY/E and 21% for Bu/Mel/T. In univariate and multivariate analyses, more advanced disease status was associated with poor outcome (TBI/CY/E: RR 0.70, CI 0.50 to 0.97 P = 0.04; Bu/Mel/T: RR 0.61, CI 0.39 to 0.97 P = 0.03). No significant differences in toxicities and outcomes were observed between these two regimens despite the inclusion of patients who had received dose-limiting irradiation in the Bu/Mel/T regimen.

Original languageEnglish (US)
Pages (from-to)455-461
Number of pages7
JournalBone Marrow Transplantation
Volume28
Issue number5
DOIs
StatePublished - 2001
Externally publishedYes

Fingerprint

Thiotepa
Whole-Body Irradiation
Busulfan
Stem Cell Transplantation
Melphalan
Non-Hodgkin's Lymphoma
Cyclophosphamide
Radiation
Drug Therapy
Disease-Free Survival
Stem Cells
Recurrence
Etoposide
Lymphoma
Multivariate Analysis
Transplantation
Transplants
Survival
Mortality

Keywords

  • Busulfan
  • High-dose chemotherapy
  • Lymphomas
  • Melphalan
  • Stem cell transplantation
  • Thiotepa

ASJC Scopus subject areas

  • Hematology
  • Transplantation

Cite this

Autologous stem cell transplantation for non-Hodgkin's lymphoma : Comparison of radiation-based and chemotherapy-only preparative regimens. / Gutierrez-Delgado, F.; Maloney, D. G.; Press, O. W.; Golden, J.; Holmberg, L. A.; Maziarz, Richard; Hooper, H.; Buckner, C. D.; Appelbaum, F. R.; Bensinger, W. I.

In: Bone Marrow Transplantation, Vol. 28, No. 5, 2001, p. 455-461.

Research output: Contribution to journalArticle

Gutierrez-Delgado, F, Maloney, DG, Press, OW, Golden, J, Holmberg, LA, Maziarz, R, Hooper, H, Buckner, CD, Appelbaum, FR & Bensinger, WI 2001, 'Autologous stem cell transplantation for non-Hodgkin's lymphoma: Comparison of radiation-based and chemotherapy-only preparative regimens', Bone Marrow Transplantation, vol. 28, no. 5, pp. 455-461. https://doi.org/10.1038/sj.bmt.1703179
Gutierrez-Delgado, F. ; Maloney, D. G. ; Press, O. W. ; Golden, J. ; Holmberg, L. A. ; Maziarz, Richard ; Hooper, H. ; Buckner, C. D. ; Appelbaum, F. R. ; Bensinger, W. I. / Autologous stem cell transplantation for non-Hodgkin's lymphoma : Comparison of radiation-based and chemotherapy-only preparative regimens. In: Bone Marrow Transplantation. 2001 ; Vol. 28, No. 5. pp. 455-461.
@article{65a9b9737bbf404fbeb0adfd05faca5c,
title = "Autologous stem cell transplantation for non-Hodgkin's lymphoma: Comparison of radiation-based and chemotherapy-only preparative regimens",
abstract = "The aim of this study was to compare toxicity and efficacy of total body irradiation (TBI), cyclophosphamide (CY) and etoposide (E) (TBI/CY/E) vs busulfan, melphalan and thiotepa (Bu/Mel/T) in patients receiving autologous stem cell infusion (ASCI) for malignant lymphoma (NHL). Between September 1990 and July 1998, 351 patients with NHL were treated with TBI/CY/E (n = 221) or Bu/Mel/T (n = 130) followed by ASCI. Patients in first, or second remission, first responding or untreated relapse were defined as having less advanced disease before transplantation. The median follow-up was 5 years (range 1-9) and 3.5 years (1-6) for patients receiving TBI/CY/E and Bu/Mel/T, respectively. The cumulative probabilities of survival, event-free survival (EFS) and relapse at 5 years were 44{\%}, 32{\%}, 49{\%} following TBI/CY/E and 42{\%}, 34{\%} and 42{\%} following Bu/Mel/T. The probability of EFS at 5 years for patients who had prior dose-limiting radiation (n = 59) was 32{\%} after Bu/Mel/T therapy. Transplant-related mortality was 16{\%} for TBI/CY/E and 21{\%} for Bu/Mel/T. In univariate and multivariate analyses, more advanced disease status was associated with poor outcome (TBI/CY/E: RR 0.70, CI 0.50 to 0.97 P = 0.04; Bu/Mel/T: RR 0.61, CI 0.39 to 0.97 P = 0.03). No significant differences in toxicities and outcomes were observed between these two regimens despite the inclusion of patients who had received dose-limiting irradiation in the Bu/Mel/T regimen.",
keywords = "Busulfan, High-dose chemotherapy, Lymphomas, Melphalan, Stem cell transplantation, Thiotepa",
author = "F. Gutierrez-Delgado and Maloney, {D. G.} and Press, {O. W.} and J. Golden and Holmberg, {L. A.} and Richard Maziarz and H. Hooper and Buckner, {C. D.} and Appelbaum, {F. R.} and Bensinger, {W. I.}",
year = "2001",
doi = "10.1038/sj.bmt.1703179",
language = "English (US)",
volume = "28",
pages = "455--461",
journal = "Bone Marrow Transplantation",
issn = "0268-3369",
publisher = "Nature Publishing Group",
number = "5",

}

TY - JOUR

T1 - Autologous stem cell transplantation for non-Hodgkin's lymphoma

T2 - Comparison of radiation-based and chemotherapy-only preparative regimens

AU - Gutierrez-Delgado, F.

AU - Maloney, D. G.

AU - Press, O. W.

AU - Golden, J.

AU - Holmberg, L. A.

AU - Maziarz, Richard

AU - Hooper, H.

AU - Buckner, C. D.

AU - Appelbaum, F. R.

AU - Bensinger, W. I.

PY - 2001

Y1 - 2001

N2 - The aim of this study was to compare toxicity and efficacy of total body irradiation (TBI), cyclophosphamide (CY) and etoposide (E) (TBI/CY/E) vs busulfan, melphalan and thiotepa (Bu/Mel/T) in patients receiving autologous stem cell infusion (ASCI) for malignant lymphoma (NHL). Between September 1990 and July 1998, 351 patients with NHL were treated with TBI/CY/E (n = 221) or Bu/Mel/T (n = 130) followed by ASCI. Patients in first, or second remission, first responding or untreated relapse were defined as having less advanced disease before transplantation. The median follow-up was 5 years (range 1-9) and 3.5 years (1-6) for patients receiving TBI/CY/E and Bu/Mel/T, respectively. The cumulative probabilities of survival, event-free survival (EFS) and relapse at 5 years were 44%, 32%, 49% following TBI/CY/E and 42%, 34% and 42% following Bu/Mel/T. The probability of EFS at 5 years for patients who had prior dose-limiting radiation (n = 59) was 32% after Bu/Mel/T therapy. Transplant-related mortality was 16% for TBI/CY/E and 21% for Bu/Mel/T. In univariate and multivariate analyses, more advanced disease status was associated with poor outcome (TBI/CY/E: RR 0.70, CI 0.50 to 0.97 P = 0.04; Bu/Mel/T: RR 0.61, CI 0.39 to 0.97 P = 0.03). No significant differences in toxicities and outcomes were observed between these two regimens despite the inclusion of patients who had received dose-limiting irradiation in the Bu/Mel/T regimen.

AB - The aim of this study was to compare toxicity and efficacy of total body irradiation (TBI), cyclophosphamide (CY) and etoposide (E) (TBI/CY/E) vs busulfan, melphalan and thiotepa (Bu/Mel/T) in patients receiving autologous stem cell infusion (ASCI) for malignant lymphoma (NHL). Between September 1990 and July 1998, 351 patients with NHL were treated with TBI/CY/E (n = 221) or Bu/Mel/T (n = 130) followed by ASCI. Patients in first, or second remission, first responding or untreated relapse were defined as having less advanced disease before transplantation. The median follow-up was 5 years (range 1-9) and 3.5 years (1-6) for patients receiving TBI/CY/E and Bu/Mel/T, respectively. The cumulative probabilities of survival, event-free survival (EFS) and relapse at 5 years were 44%, 32%, 49% following TBI/CY/E and 42%, 34% and 42% following Bu/Mel/T. The probability of EFS at 5 years for patients who had prior dose-limiting radiation (n = 59) was 32% after Bu/Mel/T therapy. Transplant-related mortality was 16% for TBI/CY/E and 21% for Bu/Mel/T. In univariate and multivariate analyses, more advanced disease status was associated with poor outcome (TBI/CY/E: RR 0.70, CI 0.50 to 0.97 P = 0.04; Bu/Mel/T: RR 0.61, CI 0.39 to 0.97 P = 0.03). No significant differences in toxicities and outcomes were observed between these two regimens despite the inclusion of patients who had received dose-limiting irradiation in the Bu/Mel/T regimen.

KW - Busulfan

KW - High-dose chemotherapy

KW - Lymphomas

KW - Melphalan

KW - Stem cell transplantation

KW - Thiotepa

UR - http://www.scopus.com/inward/record.url?scp=0035175271&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0035175271&partnerID=8YFLogxK

U2 - 10.1038/sj.bmt.1703179

DO - 10.1038/sj.bmt.1703179

M3 - Article

C2 - 11593318

AN - SCOPUS:0035175271

VL - 28

SP - 455

EP - 461

JO - Bone Marrow Transplantation

JF - Bone Marrow Transplantation

SN - 0268-3369

IS - 5

ER -